The millennial-targeted telehealth company Hims & Hers (HIMS) is spending big bucks on its first ever Super Bowl commercial ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients ... have significant health benefits beyond regulating blood sugar and suppressing appetite. Ozempic reduced the ...

Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval allows doctors to prescribe Ozempic specifically to lower the risk of kidney ...

Mounjaro was approved by the FDA in May, becoming the first combined GLP-1/GIP agonist to reach the market, but has also benefitted from supply constraints from Novo Nordisk's GLP-1 agonist ...